Your current position:
Homepage
/
/
Elsevier, publisher of The Lancet and Cell, the world's top medical journal, visited Guangmin Investment

Elsevier, publisher of The Lancet and Cell, the world's top medical journal, visited Guangmin Investment

  • Categories:News Center
  • Author:
  • Origin:
  • Time of issue:2019-11-14 00:00
  • Views:

(Summary description)On November 19, 2019, representatives of RELX Group and Elsevier, the publisher of the world's top journal Lancet and Cell, visited GDI.

Elsevier, publisher of The Lancet and Cell, the world's top medical journal, visited Guangmin Investment

(Summary description)On November 19, 2019, representatives of RELX Group and Elsevier, the publisher of the world's top journal Lancet and Cell, visited GDI.

  • Categories:News Center
  • Author:
  • Origin:
  • Time of issue:2019-11-14 00:00
  • Views:
Information

On November 19, 2019, representatives of RELX Group and Elsevier, the publisher of the world's top journal Lancet and Cell, visited GDI.

 

 

Representatives of Lucent Group and Elsevier highly appreciated the layout of Guangmin Investment in the emerging industry ecosystem.
Guangmin Investment highly respects the continuous efforts of Lucent Group and Elsevier to promote professional knowledge and information around the world. The two sides discussed the future cooperation in the fields of international science and technology and biomedicine in the Greater Bay Area of Guangdong, Hong Kong and Macao. Lin Shan, Deputy Secretary-General of Guangzhou International Exchange and Cooperation Foundation (GIF), participated in the talks.

 

Elsevier

 

Elsevier is the world's largest publisher and analysis service provider of science and technology medicine, committed to helping scientific research institutions and professionals promote scientific innovation, improve medical services and improve scientific research performance. Elsevier owns 17% of the world's peer-reviewed scientific and medical content information. It has nearly 38000 books and more than 2500 academic journals. Elsevier's publications are famous for their excellent quality and influence. Such as the top medical journals "The Lancet" and "Cell", and classic reference books, such as Gray's Anatomy "Grignard Anatomy". Almost all Nobel laureates have published their works in Elsevier. Compared with other content publications, Elsevier has published 42% of the total number of cited scientific research papers in the top 5% of China, and has maintained long-term friendly cooperation with the Chinese government and academia.
In addition to high-quality mass publications, Elsevier provides digital solutions and tools in the fields of promoting medical research, clinical decision support and professional education, including ScienceDirect, Scopus, SciVal, ClinicalKey, Via Ecology, etc. Especially in the field of medical and health care, Elsevier provides high-quality medical education content for teachers and students in the medical school, and provides strong support and help for medical professionals and patients by integrating global evidence-based medicine content into EHR/HIS and clinical workflow. Combine unique and professional content with technology, transform information into operational knowledge, and help medical professionals and patients make better decisions.

 

RELX Group

 

Elsevier is a member of the RELX Group, which is a leading provider of professional content and information solutions in the world and one of the top 500 FT. Provide scientific, medical, legal and commercial information analysis services and solutions for professionals and business customers around the world. Lucent Group has more than 30000 employees worldwide, covering 40 countries and regions on 6 continents, and providing professional services to customers in more than 180 countries.

Scan and follow our official account

               CONTACT INFORMATION

ADD:28F, No. 8, Huaxia Road, the Pearl River New Town, Tianhe District, Guangzhou

Copyright◎2023 INFINITE CAPITAL HOLDING COMPANY   粤ICP备2023032959号-1     ​BY : xinnet    Business license